Successful Phase 2 Obesity Clinical Trial in the ANZ Region for a US Biotech Company

Exceeding Targets for Phase 2 Obesity Clinical Trial 


Overview/The Challenge

PharmaSols was contracted by a small US-based biotech company to conduct a Phase 2 obesity clinical trial. The study required the recruitment of 325 eligible participants across 16 sites in Australia and New Zealand.  

New Zealand has the unfortunate statistic of having the third highest adult obesity rate in the OECD. Therefore, this, combined with over 20 years of experience across Australia and New Zealand, the PharmaSols’ team were chosen as CRO for ANZ.   

PharmaSols was chosen for our bespoke size and for being a well-connected CRO in this region. This can significantly impact the success of a clinical trial and the sponsor recognised PharmaSols for its reputation as a CRO that delivers efficient and flexible solutions within tight timelines and limited budgets. 


Overachieving Recruitment Targets

Through the selection of quality, high performing sites with strong recruitment track records, and meticulous planning and collaboration, we were able to support the first participant-first visit, which was achieved on the same day as the site activation.  

The ANZ region delivered a strong recruitment performance, and after initial global targets were reviewed, the ANZ region recruitment targets were increased to 325 participants, of which 327 participants were successfully recruited all within the study’s recruitment timelines. 


Phase 2 Obesity Trial  

Target.                        Achieved Recruitment 

325 participants         327 participants               101% 

ANZ region delivered 66% of the global target 



Innovative Strategies for Participant Retention

Obesity trials are recognised as high risk for high participant dropout rates. Dropouts occur due to various reasons, such as excess weight loss, lack of motivation, stalled weight loss, loss of muscle, and general study/time commitments. 

Understanding these challenges, PharmaSols, in partnership with the sponsor and sites, implemented creative participant-centric strategies to retain participants and minimise dropouts. These included developing participant support materials, such as an ethics-approved BMI scale for participants to monitor their weight loss, participant reimbursement for phone call visits and DXA visits, and dietitian support throughout the study. 

To implement these retention strategies, the  PharmaSols team needed to manage resubmissions to ethics committees across Australia and New Zealand to get these participant reimbursement strategies approved. Our dedicated study start-up team supported these resubmissions, quickly getting these approvals to support participant retention. 


Successful Outcomes and Strategic Impact

PharmaSols was able to support this small biotech company in running an efficient and effective clinical trial. Our deep and comprehensive service meant that we were able to guide our overseas client team and provide crucial regional support, flexibility, and tailored solutions to ensure that all regulatory and safety/quality aspects were considered and that study milestones were achieved. Our strong partnership with the client assured rapid attention and proactive solutions to any potential issues. 

With all studies, recruitment is a vital component for the overall success of a clinical trial. By delivering an increased participant targets and ensuring high-quality data outcomes, PharmaSols played a crucial role. 

The efficient execution of this Phase 2 clinical trial in the Australia and New Zealand region reflected our strong capability in managing large-scale, multi-site studies while delivering exceptional results. Our expertise in project management, site selection, participant recruitment, study start-up and regulatory compliance all contributed to the study's success. 

Case Studies

Rapid Study Start-up for Phase 1 Dermatology Study in Australia for a UK Biotech Company

PharmaSols was contracted by a small UK-based biotech company to conduct a Phase 1 dermatology clinical trial in Australia. The sponsor was looking to get the study started within a short period of time to achieve the ‘first patient in’ milestone for their investors.

Read more
PharmaSols achieve rapid start-up for complex 1b oncology study

A US-based biopharmaceutical company was looking to run a Complex 1b Oncology study. The study needed to be handled by a CRO that could manage tight timeframes, and it was imperative that it be carried out without costly interruptions.

Read more
Creating Solutions to Deliver Rapid & High-Quality Clinical Trials

Our team have needed to respond quickly to challenges supporting different studies and the experience of our team has enabled us to create rapid solutions for our global sponsors.

Read more
Expedited Timeframes and Exceeded Targets for COVID-19 Diagnostic Trial

PharmaSols were engaged by an organisation looking to run a clinical trial for a COVID-19 diagnostic test. It was imperative that this study be carried out without costly interruptions and needed to be handled by a CRO that could manage tight timeframes.

Read more
Patient Recruitment Targets Exceeded for COVID-19 Vaccine Trial

Due to PharmaSols unique location and history of successful rapid start-ups, we were engaged by a European specialty vaccine company running a COVID-19 vaccine study. This study needed to be conducted without interruptions caused by the virus itself and with a CRO that could handle tight recruitment timeframes.

Read more
Expedited Timelines and Recruitment Success for COVID-19 Vaccine Trial

While the pandemic has slowed down most of the globe, it has increased the demand for rapid solutions within the pharmaceutical industry, with an urgent need to find a vaccine and COVID-19 related treatments and vaccines. Running clinical trials for potential solutions is a vital element in this process.

Read more
Exceeding Site Identification Targets Across Three Recent Clinical Trial Studies

Site identification is the first and most critical deliverable from a CRO. Without an appropriate site, there is no patient recruitment, and without patients, there is no study.

Read more
High Recruitment: Twice as many patients as global CRO

Faced with a challenging recruitment process, needing to recruit a large number of elderly participants within a tight three-month seasonal recruitment window, a US-based Biotech Company appointed PharmaSols as the NZ CRO for this phase three respiratory clinical trial.

Read more
Rapid start-up: First SIV in less than 35 days

Having previously worked with PharmaSols over a number of trials, the US sponsor knew that the PharmaSols team could deliver on both tight start-up timelines and high recruitment targets. PharmaSols proven record of flexible, rapid, and creative solutions meant we were the ideal CRO partner.

Read more
Creative Solutions for US Biotech Clinical Trial

A US-based Biotech company was seeking a CRO who could successfully recruit a large number of elderly research participants in New Zealand. A challenge that was not only squeezed into a three-month seasonal recruitment window but was also met with issues so unique, there were no established protocols.

Read more
Rapid Start-up and Tight FPI Timeline for US Biotech Clinical Trial

After a sudden decision to expedite their study timelines, a US Biotech company approached PharmaSols in need of a CRO who could successfully achieve a quality rapid start-up within a tight timeline.

Read more
Quick Feasibility for Rare Genetic Trial

A US Biotech company reached out to PharmaSols, to investigate the feasibility of running a trial in New Zealand on participants' stored tissue samples, where consent had been given for further research to identify a rare genetic marker.

Read more